Hookipa announces positive phase 2 results for cmv vaccine candidate hb‑101

Hookipa announces positive phase 2 interim safety and immunogenicity results for its cmv vaccine candidate hb‑101.hookipa pharma inc - interim data demonstrate that hb‑101 is well tolerated.hookipa pharma inc - hb-101 elicits t cell and b cell responses in target population.hookipa pharma inc - plan to report preliminary efficacy data and updated safety and immunogenicity data by end of 2020.hookipa pharma - patients who received 3 doses of hb‑101 show comparable immunogenicity to healthy volunteers in phase 1 clinical trial of hb‑101.
SY Ratings Summary
SY Quant Ranking